mRNA Cancer Vaccine Hits Phase III Endpoint — Is Pharma the Next Big Theme After AI?

Last night brought a repricing of unusual magnitude across the pharmaceutical sector. The personalized mRNA cancer vaccine co-developed by Moderna and Merck met its key endpoint in a Phase III melanoma trial — and the read-through was immediate: Moderna shares doubled in a single session, Merck surged, and pharma majors including Eli Lilly, Johnson & Johnson, and AbbVie all notched record highs. A same-day double typically only happens when the market fundamentally reassesses its view on an entire technology pathway. The significance here may extend well beyond one product's clinical progress. Hitting a Phase III endpoint means personalized oncology vaccines have moved from proof-of-concept to the doorstep of commercial viability — and the market had, until now, priced this asset class largely on an assumption of high uncertainty. Once that assumption breaks, the valuation anchor across the broader innovative drug space needs recalibrating. The role AI plays here is worth digging into as well. Its application in pharma has been steadily extending — from early-stage target discovery and molecular design toward designing personalized treatment protocols, and personalized vaccines happen to be among the most dependent on computational capacity and data processing efficiency. In that sense, this theme represents a genuine extension of AI capability into biopharma, rather than a loosely attached narrative. The mapping effect deserves attention too: Hong Kong-listed innovative drug makers, CXOs, and upstream life science suppliers could all benefit as sentiment and capital broaden out. Beyond the AI narrative, does pharma have a real shot at becoming the next durable theme? Cancer vaccines, innovative drugs, or CXOs — which direction do you find most compelling? Flexibly allocate across core U.S. tech equities and diversified RWA portfolios on Bitget — achieve efficient cross-asset allocation and precision risk hedging: https://www.bitget.com/promotion/futures-rwa